Syndax Pharmaceuticals Inc.

281 articles about Syndax Pharmaceuticals Inc.

• Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

  4/10/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.

• Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

  4/8/2024

  Syndax Pharmaceuticals today announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) treated with revumenib, a first-in-class menin inhibitor.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 05, 2024

  4/5/2024

  Syndax Pharmaceuticals announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company's 2023 Inducement Plan.

• Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

  3/28/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced completion of enrollment in the AUGMENT-101 pivotal trial cohort of patients with relapsed/refractory (R/R) mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML).

• Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

  3/26/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for revumenib, the Company's first-in-class menin inhibitor, for the treatment of adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia.

• Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

  3/18/2024

  Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 01, 2024

  3/1/2024

  Syndax Pharmaceuticals announced that on March 1, 2024 the Company granted inducement awards to purchase up to 42,800 shares of common stock to three new employees under the Company's 2023 Inducement Plan.

• Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

  2/27/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided a clinical and business update.

• Syndax Announces Participation at Two Upcoming Investor Conferences - February 26, 2024

  2/26/2024

  Syndax Pharmaceuticals today announced that members of its management team will participate in the following sessions at two upcoming investor conferences.

• Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

  2/20/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2023 financial results and provide a business update on Tuesday, February 27, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 02, 2024

  2/2/2024

  Syndax Pharmaceuticals announced that on February 1, 2024 the Company granted inducement awards to purchase up to 127,300 shares of common stock to eight new employees under the Company's 2023 Inducement Plan.

• Syndax Announces Participation at Two Upcoming February 2024 Investor Conferences

  2/1/2024

  Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2024

  1/5/2024

  Syndax Pharmaceuticals announced that on January 1, 2024 the Company granted inducement awards to purchase up to 8,600 shares of common stock to one new employee under the Company's 2023 Inducement Plan.

• Syndax Highlights Recent Updates and Anticipated 2024 Milestones

  1/2/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today highlighted recent updates and anticipated 2024 milestones.

• Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

  1/2/2024

  Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 5:15 p.m. PT/ 8:15 p.m. ET.

• Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

  12/19/2023

  Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 12,432,431 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 1,621,621 additional shares.

• Syndax Announces Pricing of $200 Million Public Offering of Common Stock - December 15, 2023

  12/15/2023

  Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 10,810,810 shares of its common stock.

• Syndax Announces Proposed $150 Million Public Offering of Common Stock

  12/14/2023

  Syndax Pharmaceuticals, Inc. announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering.

• Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

  12/12/2023

  Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial of revumenib.

• Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

  12/11/2023

  Syndax Pharmaceuticals today announced data from multiple trials of revumenib in combination with standard of care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory (R/R) acute leukemias.